RWTH Aachen enthusiastic: California professor revolutionizes nanomedicine!
RWTH Aachen enthusiastic: California professor revolutionizes nanomedicine!
Aachen, Deutschland - Nicole Steinmetz, a renowned professor from California, was appointed Adjunct Professor on May 15, 2025 by RWTH Aachen. This award aims to strengthen cooperation with international partner universities and research institutions, such as
Professor Carsten Honerkamp emphasizes the importance of this appointment for the visibility and involvement of international researchers in the research and teaching of RWTH. Steinmetz, which is the deputy chair of the AIISO Yufeng Li Family Department of Chemical and Nano Engineering at UC San Diego, is headed by the Center for Nano-Immunoengineering and is co-director of the Center for Engineering in Cancer
stone mason looks back on an impressive scientific career that began at RWTH Aachen. After her doctorate in Bionanotechnology in Great Britain and a research station at the Scripps Research in California, she published over 300 scientific articles and submitted more than 70 patents and patent applications. Their research focuses on nanomaterials based on plant viruses and enable diverse applications in medicine and agriculture. The modifications of these nanomaterials could be used to target medication, the development of vaccines and cancer immunotherapy. A promising candidate, who has already been successfully tested in dogs with tumor diseases, is now going into clinical development. Steinmetz will also speak about the adaptation of plant virus -based platforms in pre -clinical and practical applications. Progress in nanomedicine also includes innovative approaches that advance the combination of modern virology with transgenic technologies. As part of research at the University of Bonn, lentiral vectors were established as tools in molecular biology and gene therapy. These vectors are able to transduce non-divining cells in both vivo and vivo, which is important for the gentransfer in embryonic stem cells, as University of Bonn .
These technologies are particularly relevant for the development of transgener animals as well as for the establishment of methods for targeted therapy, especially in the cardiovascular system and in the central nervous system. An important element of these technologies is the ability to target therapeutic genes in diseased cells, whereby the specific cell type can be determined by choosing the capside of the vectors. Genetically modified capsides make it possible to achieve cell types that are otherwise not recognized by any known virus particles. In addition to the development of these technologies, there is great potential in gene therapy. The creation of vectors that serve to transfer specific genes to diseased cells is a central concern of synthetic biology. The first vectors were based on naturally occurring virus sequences, and through targeted adjustments, their target accuracy can be significantly increased, such as Details research and innovation
collaboration in the field of nanomedicine
The future of gene therapy
Ort Aachen, Deutschland Quellen